12 tablets of sodium valporate 600 mg poisoning
Reading File
Finding Sources
Searching PubMed
"valproic acid" AND "overdose" AND "management"
Searching the Web
sodium valproate 7200mg overdose management treatment guidelines
Reading File
Reading Web Page
sodium valproate overdose management treatment antidote
Reading File
I now have comprehensive information. Here is the full clinical response:
Sodium Valproate Poisoning - 12 × 600 mg = 7,200 mg Ingestion
Dose Assessment
Total ingested: 7,200 mg. For a 70 kg adult, this is ~103 mg/kg - a significant overdose that exceeds the threshold for toxicologist consultation (>100 mg/kg). For a lighter patient (e.g., 50 kg), it reaches 144 mg/kg - potentially severe.
Immediate Actions (ED Management)
1. Stabilize (ABCs First)
- Secure airway - CNS depression and respiratory depression can develop rapidly and worsen as drug continues to absorb
- IV access × 2
- Cardiac monitoring and continuous SpO2
- GCS and neurological assessment
- Intubate if GCS is declining or respiratory compromise is present
2. History & Investigations
Obtain:
- Exact time of ingestion (critical - peak may be delayed 12-17 hours with enteric-coated/extended-release formulations)
- Formulation type (standard release vs. enteric-coated/CR)
- Co-ingestions (especially acetaminophen, sedatives, lithium)
- Weight of patient
Labs:
- Serum valproic acid level (serial every 4-6 hrs due to delayed absorption)
- Blood glucose (hypoglycemia is a recognized feature)
- Serum ammonia (hyperammonemia is common and can cause encephalopathy independent of sedation level)
- LFTs, amylase (hepatotoxicity, pancreatitis)
- Electrolytes including calcium, phosphate, sodium
- ABG/VBG (anion gap metabolic acidosis)
- FBC (thrombocytopenia)
- Acetaminophen and ethanol levels
- Urine ketones (VPA is partly eliminated as ketone bodies - may give false positive)
Therapeutic range: 50-100 mcg/mL. Adverse effects increase significantly above 150 mcg/mL; coma is common above 800 mcg/mL.
Clinical Features to Watch For
| Severity | Features |
|---|---|
| Mild | Drowsiness, nausea/vomiting, ataxia |
| Moderate | Lethargy, confusion, tachycardia |
| Severe | Coma, respiratory depression, hypotension, hypoglycemia, hyperammonemic encephalopathy, cerebral edema, anion gap metabolic acidosis, hepatotoxicity |
| Delayed (3-5 days) | Bone marrow suppression (thrombocytopenia), fulminant hepatic failure |
Decontamination
- Activated charcoal (AC) 50 g PO/NG if:
- Airway is protected (GCS sufficient or intubated)
- Within 1-2 hours of ingestion (can extend if enteric-coated formulation)
- No contraindications
- For enteric-coated or extended-release formulations: consider multidose activated charcoal and/or whole-bowel irrigation (polyethylene glycol) due to prolonged absorption - these can delay peak serum levels by up to 12-17 hours
- Gastric lavage within 1-2 hours if large ingestion and airway protected; some evidence supports lavage up to 10-12 hours for formulations with delayed dissolution
Antidote: L-Carnitine
L-carnitine is the most important pharmacological intervention in significant VPA toxicity. Valproate enters mitochondria using L-carnitine as a cofactor; overdose depletes carnitine stores, impairing beta-oxidation and causing mitochondrial dysfunction, hyperammonemia, and hepatotoxicity.
Indications for IV L-carnitine:
- Lethargy or depressed consciousness
- Coma
- Hyperammonemia
- Hepatic dysfunction
- Ingestion >100 mg/kg OR expected peak level >450 mg/L
Dosing (IV form preferred in symptomatic patients):
- Initial: 100 mg/kg IV (over 30 minutes; some sources recommend bolus over 2-3 min or infusion over 15-30 min)
- Maintenance: 50 mg/kg IV every 8 hours (max 3 g per dose)
- Continue until clinical improvement (resolution of encephalopathy, normalizing ammonia)
- Oral L-carnitine (3 g/day) may be used in asymptomatic patients or for mild toxicity
Enhanced Elimination
For severe overdose (VPA level >850-1000 mcg/mL, coma, cardiovascular instability, refractory acidosis):
| Method | Notes |
|---|---|
| Hemodialysis | Effective despite high protein binding - at toxic levels, free (unbound) fraction rises dramatically; reduces half-life 2-7x |
| Hemoperfusion | Effective for high protein-bound drugs; adsorbs free drug |
| CRRT + Hemoperfusion | Used in severe cases; provides hemodynamic stability alongside elimination |
| EXTRIP guidelines | Recommend extracorporeal treatment in severe cases |
Supportive Care
- Hypoglycemia: IV dextrose (VPA impairs gluconeogenesis)
- Hypotension: IV fluids; vasopressors if refractory
- Seizures: Benzodiazepines (note: VPA is the drug that was taken, so standard anticonvulsants apply; avoid phenytoin-based agents if possible)
- Hyperammonemia: L-carnitine is primary treatment; lactulose/rifaximin can be added for persistent elevation
- Cerebral edema: Head elevation, osmotherapy (mannitol/hypertonic saline) if severe
Disposition
| Scenario | Disposition |
|---|---|
| Asymptomatic, standard-release, serial levels declining | Observe in ED; discharge when levels declining and asymptomatic |
| Any symptoms, large ingestion, extended-release | Admit to medical ward or HDU |
| Coma, respiratory compromise, severe metabolic derangement | ICU admission |
| If intentional overdose | Psychiatric evaluation before discharge once medically cleared |
Key Pitfalls
- Extended-release formulations have massively delayed peak levels (up to 12-17 hrs) - do not discharge early based on an initial low level
- Hyperammonemic encephalopathy can occur at therapeutic levels and be mistaken for worsening CNS depression from other causes - always check ammonia
- Free drug fraction is much higher in overdose than predicted from protein binding at therapeutic doses
- Bone marrow suppression can be delayed 3-5 days after massive ingestion - requires follow-up FBC
Sources: Tintinalli's Emergency Medicine (9th ed.), The Washington Manual of Medical Therapeutics; Medscape Valproate Toxicity management; RCH Clinical Practice Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.